Mr. Frankl advises management teams and boards of directors on how to proactively develop and implement value creation plans and strategies that keep shareholder activism and unwelcome M&A pursuits at bay. With 20+ years of consulting experience, Mr. Frankl has led hundreds of engagements, including some of the highest profile shareholder activism and contested M&A situations in U.S. history (measured by dollar value). He has also served as an expert witness in connection with corporate governance and capital markets matters.

Mr. Frankl has also counseled hundreds of Nasdaq- and New York Stock Exchange-listed companies on the application of and strategies to achieve and regain compliance with relevant listing requirements.

Prior to joining A&M, Mr. Frankl spent 20 years with FTI Consulting, where he most recently served as Senior Managing Director and Co-Leader of the Activism and M&A Solutions practice. Before that, he served as Counsel with Nasdaq, where he conducted/or was involved in 1,000+ hearings for issuers faced with the threat of delisting or denial of initial listing for failure to satisfy Nasdaq listing standards.

Mr. Frankl was appointed by Maryland Governor Larry Hogan in 2019 to serve on the Board of Directors of the University of Maryland Medical System, a $4.8 billion medical system. He is currently Vice Chairman-elect, having served as Chairman of the Audit & Compliance Committee, Chairman of the Investments Committee, and on the Executive Compensation Committee. 

Mr. Frankl earned a bachelor’s degree in general studies from Springfield College and a J.D. from the Catholic University of America. He is a four-time honoree of the National Association of Corporate Director’s Directorship 100 list, which recognizes the most influential leaders and advisors in corporate governance.